These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 29667047)

  • 1. Investigation of the Mechanism of Therapeutic Protein-Drug Interaction Between Methotrexate and Golimumab, an Anti-TNFα Monoclonal Antibody.
    Wang W; Leu J; Watson R; Xu Z; Zhou H
    AAPS J; 2018 Apr; 20(3):63. PubMed ID: 29667047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Leu JH; Adedokun OJ; Gargano C; Hsia EC; Xu Z; Shankar G
    Rheumatology (Oxford); 2019 Mar; 58(3):441-446. PubMed ID: 30412238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of TNF-α blocker immunogenicity in psoriatic arthritis.
    Zisapel M; Zisman D; Madar-Balakirski N; Arad U; Padova H; Matz H; Maman-Sarvagyl H; Kaufman I; Paran D; Feld J; Litinsky I; Wigler I; Caspi D; Elkayam O
    J Rheumatol; 2015 Jan; 42(1):73-8. PubMed ID: 25399390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
    Boyce EG; Halilovic J; Stan-Ugbene O
    Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis.
    Xu Z; Vu T; Lee H; Hu C; Ling J; Yan H; Baker D; Beutler A; Pendley C; Wagner C; Davis HM; Zhou H
    J Clin Pharmacol; 2009 Sep; 49(9):1056-70. PubMed ID: 19617465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study.
    Zhuang Y; Xu Z; Frederick B; de Vries DE; Ford JA; Keen M; Doyle MK; Petty KJ; Davis HM; Zhou H
    Clin Ther; 2012 Jan; 34(1):77-90. PubMed ID: 22169051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Oldfield V; Plosker GL
    BioDrugs; 2009; 23(2):125-35. PubMed ID: 19489653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
    Kremer J; Ritchlin C; Mendelsohn A; Baker D; Kim L; Xu Z; Han J; Taylor P
    Arthritis Rheum; 2010 Apr; 62(4):917-28. PubMed ID: 20131276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.
    Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Lexberg AS; Rødevand E; Kalstad S; Mikkelsen K; Kvien TK
    Ann Rheum Dis; 2014 Jan; 73(1):132-7. PubMed ID: 23291385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
    Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
    Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
    Furst DE; Kay J; Wasko MC; Keystone E; Kavanaugh A; Deodhar A; Murphy FT; Magnus JH; Hsia EC; Hsu B; Xu S; Rahman MU; Doyle MK
    Rheumatology (Oxford); 2013 Oct; 52(10):1845-55. PubMed ID: 23838027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors.
    Kapetanovic MC; Roseman C; Jönsson G; Truedsson L; Saxne T; Geborek P
    Arthritis Rheum; 2011 Dec; 63(12):3723-32. PubMed ID: 21834061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor inhibitors in psoriatic arthritis.
    Mantravadi S; Ogdie A; Kraft WK
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):899-910. PubMed ID: 28490202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
    Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
    Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis.
    Tanaka Y; Senoo A; Fujii H; Baker D
    Expert Opin Drug Metab Toxicol; 2016; 12(3):319-26. PubMed ID: 26811250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension.
    Keystone EC; Genovese MC; Hall S; Miranda PC; Bae SC; Palmer W; Wu Z; Xu S; Hsia EC
    J Rheumatol; 2013 Jul; 40(7):1097-103. PubMed ID: 23678153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
    Bingham CO; Mendelsohn AM; Kim L; Xu Z; Leu J; Han C; Lo KH; Westhovens R; Weinblatt ME;
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1627-36. PubMed ID: 25623393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and survival of golimumab with and without methotrexate in patients with psoriatic arthritis: A retrospective study from daily clinical practice.
    Sharif K; Gendelman O; Langevitz P; Reitblat T; Watad A; Shoenfeld Y; Azuri J; Amital H; Bragazzi NL; Shovman O
    Best Pract Res Clin Rheumatol; 2018 Oct; 32(5):692-700. PubMed ID: 31203927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.
    Visvanathan S; Wagner C; Rojas J; Kay J; Dasgupta B; Matteson EL; Mack M; Baker DG; Rahman MU
    J Rheumatol; 2009 Jul; 36(7):1371-9. PubMed ID: 19487269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy and adverse effects of golimumab in the treatment of rheumatoid arthritis.
    Chovel-Sella A; Karplus R; Sella T; Amital H
    Isr Med Assoc J; 2012 Jun; 14(6):390-4. PubMed ID: 22891404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.